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The aim of the present article is to update our understanding of the expression of the 
insulin-like growth factor binding proteins (IGFBPs), IGFBP proteases and their impli-
cation in the different processes of ovarian folliculogenesis in mammals. In the studied 
species, IGFs and several small-molecular weight IGFBPs (in particular IGFBP-2 and 
IGFBP-4) are considered, respectively, as stimulators and inhibitors of follicular growth 
and maturation. IGFs play a key role in sensitizing ovarian granulosa cells to FSH action 
during terminal follicular growth. Concentrations of IGFBP-2 and IGFBP-4 in follicular 
fluid strongly decrease during follicular growth, leading to an increase in IGF bioavail-
ability. Inversely, atresia is characterized by an increase of IGFBP-2 and IGFBP-4 levels, 
leading to a decrease in IGF bioavailability. Changes in intrafollicular IGFBPs content are 
due to variations in mRNA expression and/or proteolytic degradation by the pregnancy- 
associated plasma protein-A (PAPP-A), and likely participates in the selection of 
dominant follicles. The identification of PAPP-A2, as an IGFBP-3 and -5 protease, and 
stanniocalcins (STCs) as inhibitors of PAPP-A activity extends the IGF system. Studies 
on their implication in folliculogenesis in mammals are still in the early stages.
Keywords: insulin-like growth factor, insulin-like growth factor binding protein, ovary, folliculogenesis, pregnancy-
associated plasma protein-A, stanniocalcins
Until the 2000s, involvement of insulin-like growth factors (IGFs) and IGF-binding proteins 
(IGFBPs) in ovarian folliculogenesis has been extensively described in several mammalian spe-
cies (1). Comparative analysis reveals some species differences concerning the role of IGFs on 
the different stages of folliculogenesis, and on the changes of levels and expression of the different 
elements of IGF system during follicular growth and atresia. In all these species, IGFs and several 
small-molecular weight IGFBPs (in particular IGFBP-2 and IGFBP-4) are considered, respectively, 
as stimulators and inhibitors of follicular growth and maturation. Based on our complete review of 
the IGF system in the mammalian ovary (1), we will present an update on IGFBPs expression and 
IGFBP proteolytic degradation in the ovary, with a focus on the protease, pregnancy-associated 
plasma protein-A (PAPP-A).
THe iGF SYSTeM
The IGF system is composed of different elements (2–4):
 – Two ligands, IGF-I and IGF-II.
 – Two receptors: the type I receptor mediates most of the somatomedin-like actions of both IGF-I 
and -II. The type II receptor, or IGF-II/Mannose-6-Phosphate (IGF-II/M6P) receptor, binds 
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IGF-II but not insulin, and binds IGF-I with very low affinity, 
and can be considered as an inhibitor of IGF-II action.
 – Six IGFBPs, which bind IGF-I and -II with high affinity. IGFBPs 
are present in all biological fluids. They can be arbitrarily clas-
sified in two groups: (1) the small molecular weight IGFBPs, 
or IGFBPs <40 kDa including IGFBP-1, -2, -4, -5, and -6 that 
are present in the serum and in other fluids in a so called 
“small complex.” When visualized by western-ligand blotting 
(WLB), their apparent molecular weights range between 
24 and 35  kDa. In serum, their levels are either negatively 
regulated (IGFBP-1 and -2) or unaffected by growth hormone 
(GH); (2) IGFBP-3, which is the predominant IGFBP in 
serum. In this fluid, it is mostly present in a 150 kDa form 
(“large complex”), composed of IGF-I or IGF-II, and an acid-
labile 85 kDa subunit (ALS). Native IGFBP-3 is visualized as a 
44–42 kDa doublet by WLB. The concentration of IGFBP-3 is 
positively regulated by GH and IGF-I.
Insulin-like growth factor binding proteins increase IGFs half-
life and constitute a large pool of IGFs in all the compartments 
of the organism (5, 6). Furthermore, IGFBPs can both inhibit 
and potentiate IGFs action at the level of target cells. They can 
indeed inhibit IGFs action by sequestration, since the affinity of 
IGFBPs for IGF-I and -II is of the same order of magnitude as the 
affinity of type I receptors. However, the affinity of IGFBPs for 
IGF-I and -II can be modulated by post-translational changes. 
Particularly, the affinity of IGFBP-1 for IGFs can be increased 
by phosphorylation as reported in human amniotic fluid at the 
end of pregnancy (2, 7, 8). Moreover, the affinity of IGFBPs for 
IGFs can be reduced when IGFBPs are bound to ECM (IGFBP-5), 
or when they are proteolyzed (IGFBP-2, IGFBP-3, IGFBP-5, and 
IGFBP-4) (3, 8). Such proteolysis has been first described in the 
serum of female rodents and humans during pregnancy, after 
nutritional fasting, during severe illness or following extensive 
trauma. Limited proteolysis of IGFBPs has also been described 
in the serum and lymph of normal human adults, and in culture 
media of osteoblastic cells, granulosa cells, and tumor cells (9). 
It is, therefore, likely that such a phenomenon exists in vivo in 
most tissues. Moreover, it is important to note that this proteolysis 
can occur at the level of the cell membrane (10). Such decreases in 
the affinity of IGFBPs for IGFs, hereby increasing bioavailability 
of IGFs, can lead to a potentiation rather than an inhibition of 
action of the ligands.
iGFs iN THe OvARY
There are many in vitro and in vivo evidence that IGF-I and IGF-II 
are stimulators of ovarian follicular development (1, 11, 12). 
IGF-I stimulates either proliferation, or differentiation of granu-
losa cells depending on the stage of development of the follicle, 
and plays a key role in the responsiveness of the ovary to FSH 
action. Moreover, the increase in expression and/or bioavail-
ability of IGFs in large preantral follicles results in an increase in 
the number of functional FSH receptors, leading to an increase 
in type I IGF receptors. This positive feedback loop might partly 
be responsible for the amplification of FSH action and the expres-
sion of aromatase and LH receptors in fully mature follicles. 
In contrast to adult rodents that have trace amounts of IGF-II 
in serum, adult humans (as well as adult sheep, cattle, and pigs), 
contain twofold to threefold more IGF-II than IGF-I in serum, 
the former being less dependent on GH than the latter. In cattle 
and mice, IGF-I seems to play a key role in increasing the sensitiv-
ity of small antral follicles to gonadotropin action, and plays a key 
role in their transition to the gonadotropin-dependent follicular 
stage. In human, circulating IGF-I does not seem to be essential 
for the development or maturation of ovarian follicles (13–15). 
In this case, it is possible that the low (likely GH-independent) 
expression of IGF-I in small growing follicles and of IGF-II in 
large dominant follicles are able to replace the contribution of 
serum GH-dependent IGF-I.
There is some heterogeneity in the localization of IGFs expres-
sion in the ovary of different species (1), but several arguments 
play in favor of a main seric origin of IGFs (16). Except in human, 
it is likely that small changes in local expression of IGFs would 
not have any significant consequence on their intrafollicular 
concentration, considering the high levels present in serum. 
Moreover in the dog, Reynaud et al. show that the wide span in 
body height among dogs with different breeds is associated with 
dramatic differences in IGF-I and IGFBP-3 levels in both plasma 
and follicular fluid from preovulatory follicles (17). These differ-
ences of levels impact follicular development: large dogs have a 
higher number of preovulatory follicles than small dogs, these 
follicles being 70% larger in the largest dog than in the smallest 
dog (17). These differences are not associated with differences 
in estradiol serum levels, suggesting an uncoupling between the 
number and the size of preovulatory follicles in this species, and 
steroidogenesis.
Actually, IGFs bioavailability, rather than IGFs concentration, 
dramatically changes during growth and atresia of ovarian fol-
licles (see below).
iGFBPs iN THe OvARY
The intrafollicular IGFBP content fluctuation is a very conserved 
phenomenon among mammalian species: the disappearance 
of IGFBPs < 40 kDa (IGFBP-2, IGFBP-4 as well as IGFBP-5 in 
ruminants follicles) characterizes the preovulatory follicles and 
the increase in their levels is observed in atretic follicles. All these 
changes are due to two processes: changes in mRNA expression, 
and changes in proteolytic degradation (Table 1).
CHANGeS iN mRNA eXPReSSiON
iGFBP-1
Most of the studies report the absence of significant expression 
of IGFBP-1 in mammalian ovaries (18–22). However, in human 
ovaries, some studies have shown IGFBP-1 mRNA expression in 
granulosa cells of mature follicles (23, 24). Overall, it could be pos-
tulated that in most mammalian species, intrafollicular IGFBP-1 
derives mainly from serum, rather than de novo synthesis.
iGFBP-2
In the ewe, the sow, the cow, and the mare, intrafollicular levels 
of IGFBP-2 strongly decrease from 1 to 2 mm diameter follicles 
TABLe 1 | General overview of IGFBP contents variations during follicular growth 
and atresia in mammalian ovary.
Growing follicles Atretic follicles
mRNA Protein Proteolysis Protein Proteolysis
IGFBP-1 Mainly from 
serum
nd nd nd
IGFBP-2 ↔/↓* ↓ ↑ ↑ 0
IGFBP-3 ↔/0* ↔ or mainly 
from serum*
nd ↔ nd
IGFBP-4 ↓/↔* ↓ ↑ ↑ 0
IGFBP-5 ↓/↔/0* ↓/0* ↑ ↑/↔/0* 0
IGFBP-6 ↔/↑* nd nd nd nd
This table summarizes global changes in follicular mRNA and protein expression levels 
of IGFBP-1 to -6 and variations in intrafollicular IGFBP proteolytic activity observed in 
most mammalian species. Species specificities are reported in the text.
*, depending on the species; ↓, decrease; ↑, increase; ↔, no change; 0, absence; nd, 
not determined.
3
Mazerbourg and Monget IGFBPs and IGFBP Proteases during Folliculogenesis
Frontiers in Endocrinology | www.frontiersin.org March 2018 | Volume 9 | Article 134
to preovulatory follicles. By contrast, its intrafollicular level 
strongly increases in atretic follicles (1, 25–28). In vivo, a strong 
decrease in IGFBP-2 mRNA expression has been observed in 
granulosa cells during follicular growth in ovine (29), porcine 
(30, 31), bovine (32), brushtail possum (33), but not in primate 
and human ovaries (24, 34). By contrast, IGFBP-2 mRNA expres-
sion has been shown to increase in the same compartment and 
in theca cells of atretic follicles in sheep (29). In the brushtail 
possum, IGFBP-2 mRNA is also expressed in granulosa and 
theca cells of atretic antral follicles (33). So in several species, 
the decrease and the increase in IGFBP-2 mRNA expression 
during follicular growth and atresia, respectively, partly explains 
changes in intrafollicular levels of the protein. In vitro, FSH and/
or cAMP strongly inhibit IGFBP-2 expression by granulosa cells 
in pigs (35, 36), in cattle (32), and humans (37), suggesting that 
the diminution of levels of this IGFBP in preovulatory follicles is 
FSH dependent (32). In the pig, the decrease in IGFBP-2 protein 
level is not associated with a decrease in mRNA levels (35, 36), 
suggesting that FSH could act through an increase in IGFBP-2 
degradation in vitro.
iGFBP-3
IGFBP-3 levels do not seem to change during folliculogenesis in 
any species. In ovarian follicles, expression of IGFBP-3 is low and 
poorly or not associated with growth or atresia (24, 38). In vitro, 
IGFBP-3 mRNA expression was positively regulated by FSH in 
small bovine granulosa cells and downregulated by estradiol in 
theca cells of large bovine follicles (39). Inversely, in cultured pig 
and human granulosa cells, FSH inhibited IGFBP-3 production 
(40, 41).
iGFBP-4
Changes in IGFBP-4 intrafollicular levels are similar to those 
observed with IGFBP-2 with a decrease in growing follicles 
and an augmentation in atretic ones (1, 25–27). In contrast to 
IGFBP-2, expression of IGFBP-4 mRNA differs between species. 
In particular, IGFBP-4 mRNA levels are low in both granulosa 
and thecal cells of ovine and bovine species, and exhibit only 
slight changes during follicular growth and atresia (32, 42). In the 
particular case of cystic ovarian disease, one of the main causes 
of infertility in dairy cattle characterized by the persistence of 
large follicular structures, IGFBP4 expression in situ is higher in 
granulosa cells in persistent follicles than in control follicles (43). 
In human ovaries, IGFBP-4 mRNA content is high in immature 
follicles and dramatically decreases in mature follicles (24). 
In the brushtail possum, IGFBP-4 mRNA is limited to theca cells 
of large preantral and antral follicles (33). In the rat, IGFBP-4 
mRNA expression strongly increases in granulosa cells of atretic 
follicles (44). This upregulation of IGFBP-4 mRNA in atretic 
rat follicles is likely due to their loss of FSH sensitivity. Indeed, 
in  vitro, FSH was shown to strongly decrease expression of 
IGFBP-4 by rat granulosa cells (45). In sharp contrast, IGFBP-4 
mRNA expression increases in thecal cells during follicular 
growth in the sow and the monkey (31, 46). In the latter species, 
7 days treatment of hCG-induced a marked increase in IGFBP-4 
mRNA expression detected by in situ hybridization in thecal cells 
in vivo (46). However, a more recent study reported a reduction 
of IGFBP-4 mRNA levels in monkey granulosa cells 24 h after 
injection of hCG (47).
In vivo, GnRHa injection in sheep, disrupting FSH and LH 
regulation, induces a significant decrease in IGFBP-4 mRNA 
expression after 36  h from start of treatment in large but not 
medium and small follicles (48). Interestingly, LH stimulates 
rather than inhibits IGFBP-4 expression by bovine thecal cells 
in  vitro (32). These results are concordant with in  vivo effects 
of hCG on IGFBP-4 expression in rhesus monkeys described 
by Zhou et al., as well as with data on the increase in IGFBP-4 
mRNA expression in large preovulatory porcine follicles (31, 46). 
However, these observations clearly contrast with the fact that in 
all these species, IGFBP-4 protein levels are undetectable in the 
follicular fluid of these follicles. This is due to its proteolysis by the 
PAPP-A protease (see below).
iGFBP-5
Ovarian expression of IGFBP-5 mRNA also strongly differs 
between species. This expression slightly decreases during fol-
licular growth in ovine thecal cells, but dramatically increases in 
granulosa cells from ovine and rat atretic follicles (42, 44, 48). In 
bovine follicles, high levels of IGFBP-5 mRNA and protein are 
detected in subordinate follicles compared to dominant follicles 
(49). In sharp contrast, in the mouse, IGFBP-5 transcript levels 
are elevated in granulosa cells of healthy primary and second-
ary follicles, and decrease in subsequent follicular stages and 
in atretic follicles (50). In rhesus monkeys, IGFBP-5 mRNA is 
selectively expressed in thecal and granulosa cells of dominant 
but not immature follicles (34). In the pig, expression of IGFBP-5 
mRNA is concentrated on the surface of the germinal epithelium 
and in capillary endothelium (20). Finally, in the brushtail pos-
sum, IGFBP-5 mRNA expression is limited to granulosa cells of 
primordial, primary, and some secondary follicles. Strong expres-
sion is also observed in the theca of secondary and antral follicles 
(33). As for IGFBP-4, FSH strongly inhibits IGFBP-5 mRNA 
expression by rat granulosa cells in vitro (45). By using a model 
of serum withdrawal-induced programmed cell death, we have 
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shown that IGFBP-5 mRNA expression is enhanced in apoptotic 
ovine granulosa cells in vitro, suggesting that the expression of 
this IGFBP is associated with cell viability in this species (28). In 
vivo, in sheep, Hastie et al. disrupted FSH and LH regulation with 
a GnRHa injection, leading to a transient increase in IGFBP-5 
mRNA expression after 12 h from start of treatment. These data 
suggest that gonadotrophins modulate IGFBP-5 expression (48).
iGFBP-6
To our knowledge, IGFBP-6 intrafollicular content has never 
been documented. In monkey ovaries, IGFBP-6 mRNA was 
present at low levels in the interstitium and theca externa and was 
more abundant in the ovary surface epithelium (34). In bovine 
follicles, IGFBP-6 mRNA has been detected only in theca cells 
with a higher expression during the final follicular growth (21). 
In cycling ewes, IGFBP-6 mRNA expression does not change in 
small follicles, no matter their health status. However, its expres-
sion significantly decreases in large atretic follicles compared to 
large healthy follicles (22).
CHANGeS iN iNTRAFOLLiCULAR 
PROTeOLYTiC DeGRADATiON
Changes in IGFBP levels during folliculogenesis can partly be 
explained by changes in intrafollicular proteolytic activity. Indeed, 
Chandrasekher et al. have shown the presence of a proteolytic activ-
ity degrading IGFBP-4 in follicular fluid from human dominant 
estrogenic but not atretic follicles (51). Proteolytic degradation of 
IGFBP-4 and -5 was also maximal in ovine, bovine, porcine, as well 
as equine preovulatory follicles (42, 52–54). IGFBP-2 proteolysis 
was also detected in follicular fluid of preovulatory follicles of the 
different mammalian species (42, 52, 53, 55, 56). Nevertheless, 
in  vivo, proteolytic degradation of IGFBP-2 likely occurs only 
in preovulatory follicles that exhibit a high IGF bioavailability, 
whereas IGFBP-4 is already degraded in healthy growing follicles. 
Interestingly, in the ewe, native IGFBP-4, assessed by WLB, was 
undetectable in follicles that contained more than 10 ng/ml estra-
diol. By contrast, native IGFBP-2 was undetectable only in follicles 
that contained more than 100 ng/ml estradiol, suggesting that the 
disappearance of IGFBP-2 during follicular growth occurs later 
than that of IGFBP-4 (1, 42). Besides, cleavage of IGFBP-2 was 
also observed after incubation with cultured mural granulosa cells 
from antral bovine follicles (57). No proteolysis was detected after 
incubation with denuded oocyte or oocyte cumulus complexes, 
suggesting that the bovine mural granulosa cells are the major 
source of the soluble protease (57). In these different conditions 
of culture, the addition of recombinant IGF-I or FSH had no effect 
on IGFBP-2 degradation rate (57).
iGFBP PROTeASeS iN THe OvARY
Pregnancy-Associated Plasma Protein-A 
(PAPP-A)
Pregnancy-associated plasma protein-A is a member of the pap-
palysin family of metzincin metallo-proteinases (58). PAPP-A 
is a large dimeric glycoprotein of 400 kDa present in increasing 
concentrations in serum during human pregnancy. It circulates 
as a 2:2 disulfide bound complex of 500 kDa with the proform 
of eosinophil major basic protein (proMBP), denoted PAPP-A/
proMBP (59, 60). No physiological function has been attributed to 
this circulating protein until Lawrence et al. showed that PAPP-A 
was the protease responsible for the proteolytic degradation of 
IGFBP-4 in human fibroblasts and osteoblasts cells-conditioned 
media (61). Then, PAPP-A was identified as the protease targeting 
IGFBP-4 in human, ovine, bovine, equine, and porcine follicu-
lar fluid (62–64). Thereafter, it was shown that IGFBP-2 was a 
substrate of PAPP-A in bovine, porcine, and equine preovulatory 
follicles (55, 56). In the mare, intrafollicular injection of PAPP-A 
into the second largest follicle (F2) decreases the concentration 
of IGFBP-2 to a level similar to the concentration in the largest 
follicle F1 (65). Finally, Rivera and Fortune have reported that 
IGFBP-5 is degraded by PAPP-A in bovine preovulatory follicles 
but not in subordinate follicles of the same cohort (64). Overall, 
these results suggest that degradation of IGFBP-2, IGFBP-4, and 
IGFBP-5 by PAPP-A in preovulatory follicles is a well-conserved 
mechanism in mammalian species. In bovine and equine ovary, 
PAPP-A, and the associated decrease in intrafollicular IGFBP-4 
level, could be a key factor in the mechanism leading to selec-
tion of dominant follicles (56, 64). In female mice, the absence 
of PAPP-A results in altered fertility, associated with reduced 
estradiol levels and reduced ovulation (66). The ovaries exhibit a 
small size but all follicular stages are present. Follicular fluid from 
Pappa knockout (KO) mice is totally deprived of IGFBP-4 pro-
teolytic activity, strongly suggesting that the altered reproductive 
capacity of these female mice is a consequence of reduced IGF 
bioavailability in the follicular compartment (66). Interestingly, 
this study highlights that the PAPP-A is the exclusive intraovar-
ian IGFBP-4 protease in the mouse. Since PAPP-A tethers to the 
surface of cells by binding to surface glycosaminoglycans, this 
protease is believed to regulate IGF signaling locally in tissues by 
increasing the pericellular level of bioactive IGF (67, 68).
PAPP-A Expression Has Been Characterized  
in the Mammalian Ovary
Several studies analyzed PAPP-A mRNA expression in the 
mammalian ovary. In the bovine and porcine ovary, a first study 
reports that PAPP-A mRNA expression in granulosa cells was 
maximal in preovulatory follicles and positively correlated with 
expression of both aromatase and LH receptors (63). In a second 
study in bovine ovary, Sudo et al. did not observe a significant 
difference of PAPP-A mRNA expression levels between follicles 
at all development stage, but the expression showed a tendency 
to increase with follicular growth (69). In a third study, Santiago 
et  al. reported neither a significant differential expression of 
PAPP-A mRNA in granulosa cells of dominant and subordinate 
bovine follicles, nor a correlation between levels of PAPP-A 
mRNA and estradiol levels in follicular fluid (49). In the rodent 
ovary, ovarian cells expressing detectable PAPP-A mRNA are the 
centrifugally located mural granulosa cells of healthy growing 
antral, as well as preovulatory follicles, and the lutein cells of the 
corpus luteum. Both PMSG and hCG strongly stimulate PAPP-A 
expression in  vivo (66, 70, 71). By in  situ hybridization in the 
human ovary, Hourvitz et al. have observed PAPP-A expression 
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in preovulatory but not immature follicles, as well as in the 
corpus luteum (72). Recently, an immunohistochemical study 
on human ovaries revealed that PAPP-A expression is primarily 
observed in the theca cells of small antral follicles, then in both 
theca and (slightly) granulosa cells of antral follicles, and finally in 
granulosa cells of preovulatory follicles (73). In that case, PAPP-A 
is co-expressed with aromatase in granulosa cells of antral and 
preovulatory follicles. Furthermore, the intrafollicular PAPP-A 
concentration is strongly positively correlated with estrogen and 
progesterone secretion and inversely correlated with testosterone 
and androstenedione levels (73). To support these expression 
data, Jepsen et al. have shown that intrafollicular concentration of 
PAPP-A increases in human antral follicles after administration 
of hCG (74). Similarly, in the rhesus monkey, PAPP-A mRNA 
expression shows a peak of induction 3 and 6 h after hCG induc-
tion leading to an increase in intrafollicular PAPP-A protein con-
centration 24 h later (47). By contrast, Zhou et al. have shown by 
in situ hybridization that PAPP-A is expressed in granulosa cells 
of antral follicles of all sizes, but did not observe any correlation 
with LH-receptor expression (46). Most of these results suggest 
a role for gonadotropin-stimulated PAPP-A gene expression 
in the shift from an androgenic to an estrogenic environment, 
characteristic of the follicular selection, as well as in the ovulation 
and luteogenesis processes in the mammalian ovary. However, 
we have to emphasize that ovarian PAPP-A protein level may not 
be systematically linked to IGFBP proteolytic activity. Indeed, in 
the human ovary, PAPP-A activity dramatically decreases in fol-
licular fluid post-hCG treatment even though the intrafollicular 
concentration of PAPP-A was still maintained at a high level (74).
In vitro, Liu et al. and Resnick et al. have shown that FSH is 
able to induce the degradation of both IGFBP-4 and IGFBP-5 by 
rat granulosa cells-derived proteases (45, 75). Later on, PAPP-A 
was identified as the protease responsible for degradation of 
IGFBP-4 in FSH-primed rat granulosa conditioned media (71). 
Interestingly, the oocyte-derived bone morphogenetic protein-15 
inhibits FSH-induced PAPP-A gene expression in rat mural and 
cumulus granulosa cell cultures. This result is likely to explain the 
absence of PAPP-A mRNA expression in the cumulus granulosa 
cells in vivo (see above) (71). In bovine granulosa cell cultures, 
Sudo et  al. further report that PAPP-A mRNA is induced by 
FSH, and estradiol amplifies this hormonal stimulation (69). 
In humans, Conover et al. have shown that PAPP-A is secreted 
in  vitro by granulosa cells from estrogen- but not androgen-
dominant follicles (76). However, they did not observe any effect 
of hCG on PAPP-A levels in cell-culture medium.
Overall, these data suggest that PAPP-A is a granulosa cells-
derived protease in the ovary and a marker of follicle selection 
and corpus luteum formation. The regulation of its expression 
highly depends on gonadotropins FSH or hCG/LH in most mam-
malian species. The involvement of intra-ovarian factors remains 
to be elucidated.
Intrafollicular PAPP-A Proteolytic Activity  
Is Modulated by IGFs
In ovine, bovine, and equine preovulatory follicular fluid, cleav-
age of IGFBP-4 and IGFBP-2 is enhanced in the presence of IGF-I 
and IGF-II (55, 56, 63). However, one can note that, in contrast to 
IGFBP-4, bovine and porcine preovulatory follicular fluids only 
induce a partial proteolytic degradation of exogenous IGFBP-2 
in the absence of exogenous IGFs with this degradation being 
clearly enhanced in the presence of exogenous IGFs (55). The 
enhancing effect of IGF is confirmed by different biochemical 
analyses, suggesting that it is due to a conformational change of 
IGFBP-4 and -2 after IGF binding, and not to the binding of IGF 
to PAPP-A (77–80). The cleavage of IGFBP-5 by PAPP-A does 
not require the presence of IGF, but is slightly inhibited by IGF 
(78, 79). Thus, the concentration of IGF is likely to control the 
dynamics of proteolysis of IGFBP-2, -4, and -5 by PAPP-A.
Intrafollicular PAPP-A Proteolytic Activity Is Not 
Modulated by Pro-MBP but by Stanniocalcins (STCs)
As stated above, PAPP-A circulates in pregnancy serum as a 
disulfide-bound complex with proMBP that is able to strongly 
inhibit PAPP-A activity. In vitro, Conover et al. failed to detect 
any proMBP in human granulosa cell-conditioned media (76). 
Since then, STCs 1 and 2 (STC1 and STC2) have been presented 
as regulators of PAPP-A activity (81, 82). STC1 binds PAPP-A 
non-covalently but with high affinity, whereas STC2 requires 
covalent binding between the two proteins (81, 82). The stable 
covalent complex STC2/PAPP-A inhibits PAPP-A proteolytic 
activity toward IGFBP-4. In mice, transgenic overexpression 
of STC2, but not of the mutated proteolytically inactive STC2, 
induces a reduction in size of up to 45% (81, 83). A similar phe-
notype is observed in transgenic mice overexpressing STC1 as 
well as in Pappa and Igf2 KO mice (84–86). The excess of STCs 
could neutralize PAPP-A activity leading to IGF sequestration 
by IGFBP-4 and a reduced local IGF bioavailability. Before the 
discovery of their new function, STC1 and STC2 expression had 
been described in some mammalian species. In the porcine ovary, 
STC1 protein was detected in theca and granulosa cells of grow-
ing follicles, in the oocyte and in luteal cells (87). A similar pattern 
of expression of STC1 protein has been observed in the mouse, 
but with the absence of expression in granulosa cells (88, 89). 
In this species, STC1 mRNA expression increases significantly 
after hCG treatment (89). In the rat, STC1 transcripts are local-
ized in theca cells and are downregulated after PMSG treatment. 
After hCG induction, their levels remain low in the theca cells 
and in the corpora lutea, which contrasts with data in the mouse 
(89, 90). Conversely, STC2 mRNA expression is limited to theca 
cell layer of rat antral and preovulatory follicles after PMSG 
stimulation. Its level keeps decreasing after hCG treatment (91). 
In cultured early antral follicles, STC2 transcripts are induced by 
estrogen (91). In granulosa cell cultures, STC1 and STC2 were 
shown to function as paracrine factors suppressing FSH-induced 
progesterone production (90, 91). Overall, in the rat, due to the 
low expression of STC1 in the PMSG-primed follicles, STC2 is 
probably the STC isoform playing a role in the inhibition of lute-
inization of preovulatory follicles (91). In humans, in contrast to 
other species in which the STCs are expressed mainly in the theca 
cells, STC1 and STC2 are coexpressed in the granulosa cells and/
or the theca-interstitial cells with variable intensity depending on 
the follicles (74). These authors showed a similar profile of expres-
sion with PAPP-A in primordial, late primary, antral follicles, and 
in the oocyte. The three proteins are consistently co-expressed 
FiGURe 1 | Dynamic of the insulin-like growth factor binding protein (IGFBP) system during folliculogenesis (1) High concentrations of IGFBP-2, IGFBP-4, and 
IGFBP-5 in follicular fluid of subordinate and atretic follicles lead to a low IGF bioavailability. The absence of IGFBP proteolytic degradation is due to the low 
expression level of PAPP-A and potentially to its association with the inhibitor STCs STC1/2. (2) During terminal follicular growth under FSH control, the decrease in 
IGFBP-2, IGFBP-4, and IGFBP-5 is due to a decrease in IGFBP mRNA expression and an increase in the proteolytic degradation by PAPP-A in follicular fluid.  
This decrease might participate in the selection of dominant follicles. At this stage, PAPP-A expression and activity are maximal. Surprisingly, the inhibitor STC1/2 is 
coexpressed with PAPP-A suggesting that STC1/2 activity could be neutralized by a partner to allow PAPP-A full activity. (3) Just before ovulation, after LH 
stimulation, PAPP-A activity is reduced likely through its association with STC1/2.
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in the same cell type during the process of follicle maturation, 
suggesting that they are able to form functional complexes (74). 
Indeed, PAPP-A:STCs complexes were immunoprecipitated in 
human follicular fluid, showing for the first time the physiological 
existence of these complexes (74). The presence of STCs could 
explain the decrease of PAPP-A activity observed in follicular 
fluid post-hCG treatment although the intrafollicular concentra-
tion of PAPP-A was still maintained at a high level (74).
Several points remain to be answered: (1) STCs are co-expressed 
with PAPP-A in human growing follicles while PAPP-A activity 
is high. Could STCs function/activity be controlled by another 
partner? (2) current studies suggest that the intra-ovarian STCs 
expression is not well conserved among species. More studies need 
to be done on the STCs protein expression rather than mRNA 
expression. Indeed, Varghese et al. have reported a different profile 
of expression in the mouse ovary between in situ hybridization 
and immunohistochemistry (88); (3) how is regulated the forma-
tion of the intrafollicular complexes PAPP-A:STCs? One could 
suggest that the expression level of each partner could influence 
their association rate; and (4) more studies are needed to define 
whether STC1 and/or STC2 are the physiological regulators of 
the PAPP-A activity. STC1 and STC2 belong to the same family 
but their protein sequences show only 30% identity (91). Due to 
the presence of additional disulfide bridges, STC2 could have a 
different tertiary structure compared to STC1 (91). However, 
both recombinant proteins STC1 and STC2 form disulfide-linked 
homodimer or an inhibitory complex with recombinant PAPP-A 
(74, 82, 91). Moreover, both STC1 and STC2 are expressed in 
human developing follicles, and are present in complexes with 
PAPP-A in follicular fluid (74, 82). At this time, it is impossible 
to delineate the relative importance of STC1 compared to STC2 
in PAPP-A inhibition; (5) The exact role of STCs in the ovary 
has to be characterized. STC1 and STC2 have been presented as 
homodimeric ligands inhibiting FSH stimulation of rat granu-
losa cells differentiation through activation of specific receptors 
(90, 91), but also as the modulators of the IGF system (74). In this 
context, studies on mice with ovarian invalidation of Stc1 and/or 
Stc2 genes would be very informative.
Pregnancy-Associated Plasma Protein-A2 
(PAPP-A2)
Pregnancy-associated plasma protein-A2, a paralog of PAPP-A, 
is responsible for the IGF-independent proteolytic degradation 
of IGFBP-5 and IGFBP-3 (92, 93). Both STC1 and STC2 can 
inhibit the activity of PAPP-A2, blocking the release of IGFs 
from IGFBP-3 and IGFBP-5 (82, 94). Homozygous loss-of-
function mutations in PAPP-A2 result in a novel syndrome of 
growth retardation with markedly elevated circulating IGF-I 
and IGF-II, but a decrease of bioactivity due to an increase in 
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serum concentrations of IGFBP-3 and -5 sequestrating IGFs (93). 
In Pappa2 KO mice, ovarian IGFBP-5 expression increases, but 
Pappa2 deletion does not affect female reproduction (95). This 
phenotype does not mimic the complex phenotype of Igfbp-5 
overexpressing transgenic mice showing reduced female fertil-
ity (96). The expression profile and the local action of ovarian 
PAPP-A2 during folliculogenesis remain to be evaluated.
CONCLUSiON
In the last two decades, studies on IGFBPs and folliculogenesis 
have been revisited with the identification of IGFBP proteases, 
PAPP-A and PAPP-A2, and more recently by the PAPP-A 
inhibitors STCs. The dynamics of ovarian IGFBP and PAPP-A 
concentrations has been linked to the selection of dominant fol-
licles. However, much is yet to be learned on the role of STCs in 
this process (Figure 1).
Most of the studies on ovarian folliculogenesis attribute an 
inhibitory function to IGFBPs by sequestrating IGFs. However, 
it is well documented that IGFBPs could favor a local action of 
IGFs by concentrating the ligand in the vicinity of the IGF recep-
tor (97, 98). Indeed, deletion of IGFBP-4 in Igfbp-4 null mice 
results in growth retardation, suggesting that loss of IGFBP-4 
leads to the loss of its pericellular reservoir function (99). 
A similar phenotype is observed in Pappa null mice with accu-
mulation of IGFBP-4. In this case, IGFBP-4 is likely to sequester 
IGF-II, prevent its release, and abolish most of IGF-II-stimulated 
growth. Then, PAPP-A could potentiate IGF action through its 
binding to the cell surface to target IGF-II/IGFBP-4 complex to 
the vicinity of the IGF receptor. Thus, these models of null mice 
highlight that IGFBP-4 can have both stimulatory and inhibitory 
effects on growth and point out the absence of any redundancy 
between IGFBPs in this context (99). What about in the ovary? 
KO mice lacking either IGFBP-2, -3, -4, or -5 and the triple 
KO IGFBP-3/-4/-5 mice are still fertile suggesting redundancy 
between IGFBPs and compensatory mechanisms (100, 101). 
Indeed, in Igfbp-2 null mice, seric IGFBP-1, IGFBP-3, and 
IGFBP-4 levels are increased relative to wild-type mice (100). 
To our knowledge, no data are available on changes of intra-
follicular IGFBP protein content. Complementary data come 
from the study on Pappa KO model showing a lower fecundity 
(reduction of the number of ovulated oocytes and the litter size), 
with no alteration of follicular growth (normal histology) (66). 
In this context, follicular fluid is deprived of IGFBP-4 proteo-
lytic activity suggesting the accumulation of IGFBP-4. It would 
be of interest to know whether high intrafollicular IGFBP-2 
and -5 levels are also maintained in the absence of PAPP-A. 
Nevertheless, this study reveals that limiting intrafollicular 
IGFBP proteolysis may decrease IGF bioavailability in growing 
follicles, but not enough to block folliculogenesis as observed in 
Igf1 null mice (11). Potential compensatory mechanisms could 
be initiated such as reduction of expression of IGFBP-2, -3, -4 
or activation of other IGFBP-2 and -5 proteases (66). Overall, in 
the mouse ovary, these results strengthen the inhibitory role of 
intrafollicular IGFBPs.
Insulin-like growth factor (IGF)-independent functions of 
IGFBPs have not been really tackled in the ovarian follicle context. 
In cancer cells, the interaction of IGFBPs with non-IGF ligands, 
the intracytoplasmic and nuclear action of IGFBPs have been 
reported (97, 98, 102). The contribution of the non-canonical 
function of IGFBPs remained to be investigated on ovarian 
cells.
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